Advertisement

Topics

Pfizer Drug Approved for Adults with Acute Lymphoblastic Leukemia

07:00 EDT 18 Aug 2017 | PharmPro

Pfizer receives U.S. FDA approval for Besponsa (inotuzumab ozogamicin). Besponsa is the only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Contributed Author: 
Pfizer Inc.

Original Article: Pfizer Drug Approved for Adults with Acute Lymphoblastic Leukemia

NEXT ARTICLE

More From BioPortfolio on "Pfizer Drug Approved for Adults with Acute Lymphoblastic Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...